| # | Drug | Count |
|---|---|---|
| 0 | NIRSEVIMAB | 2 |
| 1 | ADALIMUMAB | 1 |
| 2 | AMBRISENTAN | 1 |
| 3 | BALOXAVIR MARBOXIL | 1 |
| 4 | BORTEZOMIB | 1 |
| 5 | BUPROPION HYDROCHLORIDE | 1 |
| 6 | ELOTUZUMAB | 1 |
| 7 | ETANERCEPT | 1 |
| 8 | FLUTICASONE PROPIONATE AND SALMETEROL | 1 |
| 9 | FUROSEMIDE | 1 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NIRSEVIMAB | 2 | 0.0011 |
| 1 | BALOXAVIR MARBOXIL | 1 | 0.0004 |
| 2 | ELOTUZUMAB | 1 | 0.0002 |
| 3 | GLECAPREVIR AND PIBRENTASVIR | 1 | 0.0001 |
| 4 | VALACYCLOVIR HYDROCHLORIDE | 1 | 0.0000 |
| 5 | UPADACITINIB | 1 | 0.0000 |
| 6 | BORTEZOMIB | 1 | 0.0000 |
| 7 | BUPROPION HYDROCHLORIDE | 1 | 0.0000 |
| 8 | AMBRISENTAN | 1 | 0.0000 |
| 9 | SPIRONOLACTONE | 1 | 0.0000 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] | 2 | 0.0011 |
| 1 | SLAMF7-directed Immunostimulatory Antibody [EPC] | 1 | 0.0002 |
| 2 | Hepatitis C Virus NS3/4A Protease Inhibitor [EPC] | 1 | 0.0001 |
| 3 | Hepatitis C Virus NS5A Inhibitor [EPC] | 1 | 0.0000 |
| 4 | Proteasome Inhibitor [EPC] | 1 | 0.0000 |
| 5 | Aldosterone Antagonist [EPC] | 1 | 0.0000 |
| 6 | Janus Kinase Inhibitor [EPC] | 1 | 0.0000 |
| 7 | Endothelin Receptor Antagonist [EPC] | 1 | 0.0000 |
| 8 | Loop Diuretic [EPC] | 1 | 0.0000 |
| 9 | Tumor Necrosis Factor Blocker [EPC] | 1 | 0.0000 |